Cargando…
1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation
BACKGROUND: The risk of latent tuberculosis infection (LTBI) reactivation in cancer patients during checkpoint inhibitor immunotherapy (CPI) remains largely unknown. We sought to evaluate LTBI therapy and outcomes between cancer patients receiving CPI versus conventional chemotherapy (CC) and hemato...
Autores principales: | Malek, Alexandre, Chaftari, Patrick, dagher, Hiba, Hachem, Ray Y, Chaftari, Anne-Marie, Viola, George, Raad, Issam I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777861/ http://dx.doi.org/10.1093/ofid/ofaa439.1816 |
Ejemplares similares
-
1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021) -
1228. The Role of Procalcitonin (PCT) and Lactic Acid in Febrile Neutropenic Cancer Patients in an Oncological Emergency Center
por: Chaftari, Patrick, et al.
Publicado: (2020) -
357. A Comparison of Chest CT Findings in Cancer and Non-Cancer Patients with COVID-19
por: Malek, Alexandre, et al.
Publicado: (2021) -
1769. The Impact of Checkpoint Inhibitor Immunotherapy on Infections in Lung Cancer Patients
por: Malek, Alexandre, et al.
Publicado: (2019) -
528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)